The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Chemotherapy in Pharmaceuticals: Platinum-based cancer drug compositions.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Platinum-based cancer drug compositions is a key innovation area in chemotherapy
Platinum-based drugs are chemotherapeutic agents used for the treatment of cancer. Several platinum-based drugs such as cisplatin, carboplatin and oxaliplatin are widely used in cancer therapy. These compounds cause their therapeutic effect by inhibiting DNA synthesis.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 320+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of platinum-based cancer drug compositions.
Key players in platinum-based cancer drug compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to platinum-based cancer drug compositions
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Bristol-Myers Squibb||281||Unlock company profile|
|F. Hoffmann-La Roche||258||Unlock company profile|
|Otsuka Holdings||250||Unlock company profile|
|Vertex Pharmaceuticals||247||Unlock company profile|
|E. Merck||184||Unlock company profile|
|Eli Lilly and||167||Unlock company profile|
|Amgen||130||Unlock company profile|
|Pharma Mar||120||Unlock company profile|
|Pierre Fabre Foundation||115||Unlock company profile|
|Bayer||113||Unlock company profile|
|Pfizer||101||Unlock company profile|
|Ipsen||86||Unlock company profile|
|AbbVie||80||Unlock company profile|
|Regeneron Pharmaceuticals||79||Unlock company profile|
|C. H. Boehringer Sohn||79||Unlock company profile|
|Johnson & Johnson||78||Unlock company profile|
|Eagle Pharmaceuticals||71||Unlock company profile|
|Esteve Pharmaceuticals||70||Unlock company profile|
|Merrimack Pharmaceuticals||68||Unlock company profile|
|Arcus Biosciences||61||Unlock company profile|
|Takeda Pharmaceutical||61||Unlock company profile|
|Mayo Clinic||60||Unlock company profile|
|Komipharm International||60||Unlock company profile|
|Novartis||59||Unlock company profile|
|Spectrum Pharmaceuticals||58||Unlock company profile|
|TesoRx Pharma||55||Unlock company profile|
|GSK||53||Unlock company profile|
|CanBas||52||Unlock company profile|
|NanoCarrier||47||Unlock company profile|
|City of Hope||46||Unlock company profile|
|Sprint Bioscience||45||Unlock company profile|
|Merck & Co||45||Unlock company profile|
|Promontory Therapeutics||45||Unlock company profile|
|Sanofi||45||Unlock company profile|
|Mallinckrodt||45||Unlock company profile|
|Eisai||44||Unlock company profile|
|NuCana||44||Unlock company profile|
|Bio-Bedst||44||Unlock company profile|
|Centre National de la Recherche Scientifique||43||Unlock company profile|
|Astellas Pharma||43||Unlock company profile|
|LEAF Holdings Group||42||Unlock company profile|
|Aslan Pharmaceuticals||42||Unlock company profile|
|Superlab Far East||41||Unlock company profile|
|United Nations Industrial Development Organization||41||Unlock company profile|
|MEI Pharma||40||Unlock company profile|
|Ono Pharmaceutical||39||Unlock company profile|
|Polaris Pharmaceutical Group||39||Unlock company profile|
|Myriad Genetics||38||Unlock company profile|
|Intezyne||37||Unlock company profile|
|Nippon Kayaku||36||Unlock company profile|
Source: GlobalData Patent Analytics
Bristol-Myers Squibb is one of the leading patent filers in platinum-based drugs. The company has filed several patents involving platinum compounds and developed drugs such as cisplatin and carboplatin..
In terms of application diversity, Synlogic is the top company, followed by Traslational Cancer Drugs Pharma and
Calgent Biotechnology. By means of geographic reach, Nanobiotix holds the top position. BioMarin Pharmaceutical and Eisai are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.